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ABSTRACT
Background Reported prevalence, penetrance and
expression of deleterious mutations in the mismatch
repair (MMR) genes, MLH1, MSH2, MSH6 and PMS2,
may reﬂect differences in the clinical criteria used to
select families for DNA testing. The authors have
previously reported that clinical criteria are not sensitive
enough to identify MMR mutation carriers among
incident colorectal cancer cases.
Objective To describe the sensitivity of the criteria
when applied to families with a demonstrated MMR
mutation.
Methods Families with an aggregation of colorectal
cancers were examined for deleterious MMR mutations
according to the Mallorca guidelines. All families with
a detected MMR mutation as of November 2009 were
reclassiﬁed according to the Amsterdam and Bethesda
criteria.
Results Sixty-nine different DNA variants were identiﬁed
in a total of 129 families. The original Amsterdam clinical
criteria were met by 38%, 12%, 78% and 25% of families
with mutations in MSH2, MSH6, MLH1 and PMS2,
respectively. Corresponding numbers for the revised
Amsterdam criteria were 62%, 48%, 87% and 38%.
Similarly, each of the four clinical Bethesda criteria had
low sensitivity for identifying MSH6 or PMS2 mutations.
Conclusion Amsterdam criteria and each of the
Bethesda criteria were inadequate for identifying MSH6
mutation-carrying kindreds. MSH6 mutations may be
more common than currently assumed, and the
penetrance/expression of MSH6 mutations, as derived
from families meeting current clinical criteria, may be
misleading. To increase detection rate of MMR mutation
carriers, all cancers in the Lynch syndrome tumour
spectrum should be subjected to immunohistochemical
analysis and/or analysis for microsatellite instability.
INTRODUCTION
The concept of hereditary non-polyposis colorectal
cancer (HNPCC) was developed to denote families
with inherited colorectal cancer (CRC). The
Amsterdam (AMSI) criteria identiﬁed families with
CRC.
1 As extracolonic cancers, especially endome-
trial cancer, were shown to be part of the inherited
syndrome,
23the revised Amsterdam criteria
(AMSII) were introduced.
4 The Bethesda guidelines
included the tumour marker microsatellite insta-
bility (MSI),
5 and the revised Bethesda criteria (BII)
speciﬁed all cancers known at the time to be asso-
ciated with the syndrome.
6 Prostate cancer has
recently been shown to possibly be part of the
syndrome.
7 Germline mutations in the mismatch
repair (MMR) genes, MLH1, MSH2, MSH6 and
PMS2, have been identiﬁed to cause HNPCC
(reviewed by Lynch and Lynch
8). However, it has
become clear that not all families fulﬁlling the
clinical criteria have an identiﬁable deleterious
mutation (hereafter called ‘mutation’) in one of
these genes. In addition, because MMR mutations
confer an increased risk of several types of cancer in
addition to CRC, it has been suggested that the
term Lynch syndrome should replace HNPCC in
families where a mutation has been detected.
9 This
deﬁnition of Lynch syndrome will be used in the
present report. Families fulﬁlling the AMSII criteria
without a demonstrable MMR mutation may be
denoted HNPCC. Families with an aggregation of
CRC and not corresponding to Lynch syndrome or
HNPCC may be referred to as familial CRC.
9
Tumours caused by mutations in MLH1, MSH2,
MSH6 and PMS2 show a high degree of MSI. It has
been shown by immunohistochemical analysis
(IHC) that the gene product from the mutated gene
is absent in tumour tissue (reviewed by Vasen et al
10).
IHC and MSI analysis have high sensitivity in
detecting carriers of MMR mutations.
11 12 It is now
customary to examine tumours in families that fulﬁl
clinical criteria by IHC/MSI analysis, and select
those families with abnormal results for analysis of
constitutional DNA.
10 As a consequence, families
not meeting the clinical criteria will not be subjected
to mutation analyses.
Varying prevalence of mutations in the MMR
genes has been reported. Some variations are obvi-
ously caused by geographically local and frequent
founder mutations.
13e16 It is, however, reasonable
to assume that the criteria used to select families
for testing may also have inﬂuenced the results.
Over the last two decades, Norwegian cancer
genetic clinics have recruited families with an aggre-
gation of cancers of any type. Thousands of cancer
kindreds have been examined for hereditary cancer
syndromes. Reports from this are listed on http://
www.inherited-cancer.com. Upon referral, the fami-
lies were classiﬁed using preset wide-ranging criteria,
and IHC/MSI analyses were performed not only on
the families that met the clinical criteria for HNPCC
and familial CRC. We here report the sensitivities of
the AMSI, AMSII and BII criteria when applied to
families that were shown by genetic testing to have
an MMR mutation. As Norwegian legislation
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Original articledictates that genetic testing is restricted to clinical departments,
and as all genetic departments collaborated in this report, we here
present a complete report of all clinical genetic activity in a deﬁned
population up to November 2009.
PATIENTS AND METHODS
Patients, registries and ethics
The initial material included all families investigated for
inherited CRC in Norway until November 2009. Wide-ranging
selection criteria were used to identify the families. Besides
including all kindreds meeting the AMSII or BII criteria, we
explored all families with four CRC cases irrespective of age and
including skipped generations or with an aggregation of any
cancer associated with Lynch syndrome. All activities were
conducted as part of the healthcare system, all information was
included in the patient ﬁles, all genetic testing was conducted
according to national legislation, including genetic counselling
before and after genetic testing, and all genetic testing was
performed with written informed consent from the participants.
All relevant diagnoses in the families were validated in the
medical ﬁles or cancer registry after consent from relatives or
descendants if the subject was dead. No research registry that
included names was produced; only summarised data were taken
from medical ﬁles for compilation of the present report. All
information described has been disclosed to the patients/fami-
lies, and family members were offered appropriate healthcare
according to the Mallorca guidelines.
9
MSI/IHC examinations
Upon referral and inclusion according to the wide-ranging
criteria, families were subjected to examination for Lynch
syndrome as described in the Mallorca guidelines, with IHC/
MSI analysis of at least two affected family members if avail-
able,
9 continuing to full mutation analysis of the relevant gene(s)
of the patient (or obligate carrier in the family or offspring if
dead) if an abnormal IHC result was obtained. A family was
scored as having an abnormal IHC result if one or more tumour(s)
showed lack of staining for the gene product of one or more
of the MMR genes. Full mutation analysis of all MMR genes
was performed if IHC was normal but the tumours were MSI
(MSI-high). In some selected families, mutation analyses were
also performed in the absence of MSI/abnormal IHC.
Molecular methods
MMR mutation analyses included heteroduplex identiﬁcation
followed by DNA sequencing of the actual MMR gene(s).
Analysis of gross deletions and duplications was performed by
multiplex ligation-dependent probe ampliﬁcation assay (MLPA;
SALSA P003 MLH1/MSH2, P008 MSH6/PMS2 and P072-MSH6;
MRC-Holland, http://www.mrc-holland.com). Results for
PMS2 exon 13e15 probes were disregarded because many
related sequences are present in the genome and the probes
provided very variable results. Sequencing analyses were
performed on an ABI Genetic Analyzer model 3100 or 3130
(Applied Biosystems, Carlsbad, CA, USA), and DNA sequences
were computed using SeqScape v2.5 software (Applied Biosys-
tems). Primer and sequence details are available on request. In
some cases of putative splice effects, cDNA analyses of MLH1,
MSH2, MSH6 and PMS2 were performed. The molecular anal-
yses were performed according to standard procedures and
manufacturers’ instructions. Methods used varied over time and
between the different laboratories involved. It was beyond our
means to reanalyse the whole series so that one method was
applied to all cases for the present report.
Classiﬁcation of DNA variants
Reference sequences used were as follows (GeneBank http://
www.ncbi.nlm.nih.gov/genbank): MLH1, NT_022517 (transcript:
NM_000249.2); MSH2, NT_022184 (transcript: NM_000251.1);
MSH6, NT_0221844 (transcript: NM_000179.1); PMS2,
AC005995.3 (transcript: BC093921.1). Detected DNA variants
were checked against published mutations in the following
websites: http://www.insight-group.org (LOVD: Leiden Open
Variation Database), https://portal.biobase-international.com/
hgmd/pro/start.php (Human Gene Mutation Database), Pub
Med and http://www.med.mun.ca/MMRvariants.
17 Mutations
causing direct stop/nonsense, frameshifts, splice defects and large
insertions/deletions were considered deleterious. Missense
mutations or small in-frame deletions were subjected to segre-
gation analysis when possible.
18 If a review of the international
databases or segregation analyses strongly suggested the variant
to be deleterious, the mutations were scored accordingly. The
reasons for scoring of each mutation are given in table 1. All
other DNA variants were considered part of normal variation or
the information available on the variant and family was insuf-
ﬁcient for conclusive scoring. These variants were excluded from
the report.
Clinical classiﬁcation
All families in which an MMR mutation (ie, with conﬁrmed
Lynch syndrome) had been detected were reclassiﬁed according
to clinical criteria with the information obtained as of
November 2009. Thus the classiﬁcation does not reﬂect the
starting point with the information at hand at referral, but
rather the information obtained after having expanded all Lynch
syndrome families and veriﬁed all relevant diagnoses for all
family members in the medical ﬁles or cancer registry. The
families were classiﬁed according to the AMSI, AMSII or BII
criteria. Furthermore, the scoring for BII criteria was speciﬁed
according to the subgroups given in Umar et al
6: BII_1
(CRC<50 years), BII_2 (synchronic/metachronic cancers), BII_4
(two affected relatives, one <50 years) and/or BII_5 (relatives
with HNPCC-associated tumours). For precise deﬁnitions of
groups as applied, see Umar et al.
6 BII_3 includes MSI, which
was a selection criterion for DNA analysis, and was not used to
categorise mutation-carrying kindreds revealed this way. Also,
MSI is a laboratory ﬁnding and not a clinical criterion. The
combined BII criteria were possibly too close to our inclusion
criteria for the total cohort studied, and scoring for the
combined BII criteria could not be considered a result.
RESULTS
Sixty-nine different mutations were identiﬁed in a total of 129
families. Of these, 31 (45%) were detected in MSH2, 19 (27%) in
MSH6, 15 (22%) in MLH1, and four (6%) in PMS2. Sixty-ﬁve
(50%) of the families had a mutation in MSH2, 33 (26%) in
MSH6, 23 (18%) in MLH1, and eight (6%) in PMS2. The total
numbers of mutation carriers were 514, of whom 248 (48%), 146
(28%), 98 (19%) and 22 (4%) had a mutation in MSH2, MSH6,
MLH1 and PMS2, respectively.
Frameshift mutations (n¼24) and splice defects (n¼18) were
the most common aberrations. Other types of mutations were
nonsense mutations creating new stop codons (n¼13), large
genomic (exon) deletions (n¼8), in-frame deletions of three
nucleotides (n¼3) and missense mutations (n¼3). There were no
indications that the nature of mutations differed between the
different genes, and no further statistical analyses based on the
nature of the mutation were undertaken.
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Original articleTable 1 Deleterious mismatch repair (MMR) mutations in the Norwegian population
22 31
Type of
mutation/ gene Mutation
Effect of mutation
(veriﬁed or predicted) Family No
No of
mut+
IHC (missing
protein)
Inclusion criteria:
Amsterd.zz
Inclusion
criteria: BII xx Ref.
Frameshift
MLH1e1 c.39_40dupGA p.Thr14ArgfsX3 H1855 (D4354) 6 MLH1/PMS2 I & II 1, 2, 4 & 5 LOVD
T343 1 MLH1/PMS2 I & II 1, 2, 4 & 5
D20 1 MLH1/PMS2 I & II 1, 2, 4 & 5
MLH1e5 c.413delC p.Pro138LeufsX21 U82517 1 MLH1/PMS2 I & II 1, 2, 4 & 5 {{
MLH1e10 c.866_867delAC p.His289ProfsX16 H836 2 MLH1/PMS2 I & II 1, 2, 4 & 5 LOVD
MLH1e13 c.1411_1414delAAGA p.Lys471AspfsX19 H892* 3 MLH1/PMS2&
MSH2/MSH6
II 1& 5 LOVD
MLH1e16 c.1771dupG p.Asp591GlyfsX1 U97760 3 MLH1&PMS2 I & II 1, 2, 4 & 5 {{
MSH2e2 c.229_230delAG p.Ser77CysfsX3 H3323 1 MSH2/MSH6 0 1 LOVD
MSH2e4 c.675_678delAGAA p.Thr225ThrfsX19 D2679 1 MSH2/MSH6 II 1, 4 & 5 {{
MSH2e6 c.969_970delTC p. Gln324ValfsX8 U85816 2 MSH2/MSH6 I & II 1, 2, 4 & 5 {{
D2033 1 MSH2/MSH6 I & II 1, 2, 4 & 5
MSH2e7 c.1204delC p.Gln402LysfsX10 H677 1 MSH2/MSH6 II 1, 4 & 5 LOVD
MSH2e10 c.1594dupG p.Val532GlyfsX3 D139 5 MSH2/MSH6 I & II 1, 2, 4 & 5 LOVD
MSH2e11 c.1705_1706delGA p.Glu569IlefsX1 D2938 4 MSH2/MSH6 II 1, 2, 4 & 5 LOVD
MSH2e13 c.2120_2122delGCA
insCGGGCTAAGAAGTG
p.Cys707SerfsX2 D1570 5 MSH2/MSH6 I & II 1, 2, 4 & 5 {{
MSH6e4 c.900dupG p.Lys301GlufsX11 U88612 2 MSH2/MSH6 II 2, 4 & 5 {{
MSH6e4 c.1405delT p.Tyr469IlefsX11 S254 9 normaly II 5 {{
MSH6e4 c.1943delG p.Ser648MetfsX5 H2327 3 MSH2/MSH6 0 1, 2 & 4 {{
MSH6e4 c.2604delG p.Met868IlefsX5 D1731 3 MSH6 II 2 & 5 {{
MSH6e5 c.3195_3199delCTATA p.Asn1065LysfsX4 D2115 5 MSH6 II 1, 4 & 5 LOVD
MSH6e5 c.3261dupC p.Phe1088LeufsX5 H1408 1 MSH6 I & II 1, 4 & 5 LOVD
S631 7 MSH6 0 1 & 2
S1108 4 MSH6 II 1, 2 & 4
T02 2 MSH2/MSH6 I & II 1, 2, 4 & 5
MSH6e5 3261delC p.Phe1088ProfsX2 D867 8 MSH6 0 2 & 5 LOVD
MSH6e6 c.3514dupA p.Arg1172LysfsX4 U94618 1 MSH6 II 2 LOVD
MSH6e9 c.3804dupA p.Cys1269MetfsX5 U61010 7 MSH2/MSH6 0 2 & 5 LOVD
U98731 2 MSH6 II 2, 4 & 5
U1000922 2 MSH6 0 0
U1003522 1 MSH6 0 1 & 5
D1151 4 MSH6 0 2 & 5
S889 1 MSH6 0 2
MSH6e9 c.3832_3845del14 p.Pro1278_1282delfsX6 U1000116 1 MSH6 II 4 & 5 {{
PMS2e7 c.736_741delCCCCCT
insTGTGTGTGAAG
p.Pro246CysfsX2 U97751 1 PMS2 0 1 & 5 LOVD
PMS2e14 c.2382dupT p.Gly795TrpfsX29 T92 3 PMS2 0 2 & 5 {{
Splice defect
MLH1int9 c.790+1G/A Skipping of exon 9-10 H285 2 ND 0 1, 4 & 5 LOVD
MLH1int9 c.791e2A/G Splice defect T04 (S639 & H1547)) 8 MLH1/PMS2 I & II 1, 2, 4 & 5 LOVD
MLH1e10 c.793C/T p.Arg265Cysz D490 10 MLH1/PMS2 I & II 1, 2, 4 & 5 LOVD
MLH1e15 c.1731G/C Skipping of exon 15x U1001245 3 MLH1/PMS2 I 1, 2, 4 & 5 LOVD
(c.1731G/A)
MLH1int15 c.1731+1G/C Splice defect D1532 1 MLH1/PMS2 II 1, 2, 4 & 5 LOVD
MSH2e5 c.815C/T r.(¼)+(¼; 793_942del){ S403 5 MSH2/MSH6 0 2, 4 & 5 LOVD
MSH2int5 c.942+3A/T r.(¼)+(793_942del){ H07 5 ND II 1, 2, 4 & 5 LOVD
H892* 3 MSH2/MSH6 II 1, 2, 4 & 5
H1503 (S551) 4 MSH2/MSH6 0 1, 2, 4 & 5
H1598 (S583) 3 MSH2/MSH6 II 1, 2, 4 & 5
H2215 4 MSH2/MSH6 I & II 1, 2, 4 & 5
H2280 1 MSH2/MSH6 0 1, 2, 4 & 5
U101185 1 MSH2/MSH6 II 1, 4 & 5
T059 3 MSH2/MSH6 0 1, 4 & 5
T073 9 MSH2/MSH6 0 1, 2, 4 & 5
D637 3 MSH2/MSH6 0 4 & 5
D1211 11 MSH2/MSH6 I & II 1, 2, 4 & 5
D4522 2 MSH2/MSH6 0 1, 2 & 5
MSH2int6 c.1076+1G/A Skipping of exon 6 H1903 5 MSH2/MSH6 0 1, 4 & 5 LOVD
D1773 5 MSH2/MSH6 0 2 & 5
MSH2int7 c.1277e2A/G r.(¼, 1277_1386del){ S577 9 MSH2/MSH6 I & II 1, 2 & 4 LOVD
Continued
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Type of
mutation/ gene Mutation
Effect of mutation
(veriﬁed or predicted) Family No
No of
mut+
IHC (missing
protein)
Inclusion criteria:
Amsterd.zz
Inclusion
criteria: BII xx Ref.
S612 4 MSH2/MSH6 0 1, 2 & 4
D671 2 MSH2/MSH6 II 1, 2, 4 & 5
MSH2int10 c.1661+1G/A Splice defect D470 2 MSH2/MSH6 II 1, 2, 4 & 5 LOVD
MSH2e11 c.1759G/C r.(¼, 1662_1759del)x { S959 2 MSH2/MSH6 0 1, 2 & 4 LOVD
MSH2int11 c.1759+2T/A Deletion exon 12, 13 D971 1 MSH2/MSH6 I & II 1, 2, 4 & 5 LOVD
MSH2e12 c.1979A/G r.(¼, 1979_2005del){ U74987 1 MSH2/MSH6 0 1, 2, 4 & 5 31
MSH2int12 c.2006e1G/C splice defect D2013 3 MSH2/MSH6 I & II 1, 2, 4 & 5 LOVD
MSH2int15 c.2634+1G/T r.(¼, 2459_2634del) H246/275 10 ND I & II 1, 4 & 5 LOVD
MSH6int7 c.3647e2A/C r.(¼, 3646_3647ins3646
+1_3646+492){
S819
(U100998&U104021)
10 MSH6 II 1, 2 & 4 LOVD
D686 7 MSH6 II 0
PMS2intr5 c.537+1G/T Splice defect H3118 2 PMS2 0 1 {{
PMS2int9 c.989e1G/T r.(¼)+(989_1144del,
989_1015del){
S90 4 normal (MSI)** 0 1, 2 & 4 22
S335 1 normal (MSI)** II 1, 2
S350 4 PMS2 I & II 1 & 4
S1147 2 normal (MSI)** 0 1
D3786 5 PMS2 I & II 1, 2, 4 & 5
Stop codon
MLH1e2 c.184C/T p.Gln62X H321 8 ND I & II 1, 4 & 5 LOVD
H480 4 ND I & II 1, 2, 4 & 5
H487 3 MLH1/PMS2 I & II 1, 2, 4 & 5
D498 9 MLH1/PMS2 I & II 1, 2, 4 & 5
D874 4 MLH1/PMS2 I & II 1, 2, 4 & 5
D1704 5 MLH1/PMS2 I & II 1, 2, 4 & 5
MSH2e1 c.142G/T p.Glu48X U1101385 1 MSH2/MSH6 0 1 & 5 LOVD
U101386 1 MSH2/MSH6 II 1, 4 & 5
MSH2e1 c.181C/T p.Gln61X D3959 3 MSH2/MSH6 II 1 & 5 LOVD
MSH2e2 c.226C/T p.Gln76X D271 2 MSH2/MSH6 0 1, 2, 4 & 5 LOVD
MSH2e12 c.1857T/G p.Tyr619X D3648 4 MSH2/MSH6 0 1, 2, 4 & 5 LOVD
MSH2e13 c.2038C/T p.Arg680X U59124 1 MSH2/MSH6 I 1, 2, 4 & 5 LOVD
D414 7 MSH2/MSH6 I & II 1, 2, 4 & 5
MSH2e14 c.2275G/T p.Gly759X D1661 4 MSH2/MSH6 0 1, 2, 4 & 5 LOVD
MSH6e3 c.467C/G p.Ser156X D1651 1 MSH6 0 5 LOVD
MSH6e4 c.718C/T p.Arg240X D4216 2 MSH6 0 1, 2, 4 & 5 LOVD
MSH6e4 c.1444C/T p.Arg482X S407 5 MSH2/MSH6 I & II 1, 2 & 4 LOVD
S1003 10 MSH6 0 5
MSH6e4 c.1483C/T p.Arg495X S363 5 MSH2/MSH6 II 2 & 4 LOVD
MSH6e4 c.2731C/T p.Arg911X D1316 7 MSH6 0 1, 2 & 5 LOVD
MSH6e9 c.3991C/T p.Arg1331X H1522 5 ND 0 1, 2 & 4 LOVD
D1826 10 MSH6 0 5
Exon deletion
MLH1 c.546-?_790+?del del exon 7e9 S499 (H1102) 11 MLH1/PMS2 I & II 1, 2, 4 & 5 LOVD
D2020 4 MLH1/PMS2 I & II 1, 2, 4 & 5
MLH1 c.1732-?_1896+?del del exon 16 H2094 1 ND I 1, 4 & 5 LOVD
MSH2 c.1-?_366+?del del exon 1e2 S541 2 MSH2/MSH6 0 1, 2 & 4 LOVD
MSH2 c.1-?_1076+?del del exon 1e6 H592 3 MSH2/MSH6 0 1, 2, 4 & 5 LOVD
D1718 4 MSH2/MSH6 0 1, 2, 4 & 5
MSH2 c.1-?_1276+?del del exon 1e7 U81431 2 MSH2/MSH6 I & II 1, 2, 4 & 5 LOVD
MSH2 c.1-?_1661+?del del exon 1-10 D3824 3 MSH2/MSH6 0 1 & 5 LOVD
MSH2 c.212-?_1276+?del del exon 2-7 H346 3 ND I & II 1, 2, 4 & 5 LOVD
H496 1 MSH2/MSH6 II 1, 4 & 5
H1110 (S604) 9 MSH2/MSH6 II 1, 2, 4 & 5
S81 5 MSH2/MSH6 I & II 1, 4 & 5
S281(U1002732) 8 MSH2/MSH6 I & II 1, 2, 4 & 5
S649 6 MSH2/MSH6 II 1, 2 & 4
D2107 7 MSH2/MSH6 I & II 1, 2, 4 & 5
MSH2 c.367-?_645+?del del exon 3 H400 4 MSH2/MSH6 I & II 1, 4 & 5 LOVD
In-frame deletion
MSH2e3 c.571_573delCTC p.Leu191del H1294 1 MSH2/MSH6 I & II 1, 2, 4 & 5 {{
H2544 1 MSH2/MSH6 0 1 & 5
H3517 1 ND 0 4
Continued
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Original articleDetails on the prevalence of each mutation are given in
table 1. Forty-nine of the 69 mutations were exclusively found in
one family. There were no mutations that were frequent enough
to have a signiﬁcant effect on the distributions observed
between the different genes. The most recurrent mutation,
MSH2 c.942+3A/T, was found in 12 apparently unrelated
families (49 people) from different geographical locations and
has been described in other populations.
19e21 It has possibly
been introduced more than once into our population. The
majority of the remaining recurrent mutations could be traced
to conﬁned geographical areas and were considered to be
branches from a common origin (founder mutations). Families
with deleterious PMS2 mutations were limited. One single
mutation (c.989e1G/T)
22 accounted for the majority of PMS2
mutation-carrying kindreds, all from the same (small) area.
Average numbers of demonstrated mutation carriers per family
were similar for all mutations; details are shown in table 2.
Tumour tissue was available for IHC and MSI analysis for
most of the families later demonstrated to have an MMR
mutation. The IHC results are shown in table 1. All but ﬁve
families showed abnormal IHC corresponding to the gene
mutated. Tumours from three of ﬁve kindreds with the founder
PMS2 splice variant, c.989e1G/T, mentioned above expressed
PMS2 normally but showed MSI (MSI-high). Similarly, tumour
tissue from one family with a missense mutation in MLH1
(c.245C/T (p.Thr82Ile)) showed normal IHC and MSI (MSI-
high). Apparently normal expression of MLH1 indicated by IHC
in MSI-high tumours is in agreement with another report.
23 In
the family with the c.1405delT, in MSH6, the tumour showed
normal IHC and was microsatellite stable (MSS).
The mutation-positive families that fulﬁlled the various clin-
ical criteria when reclassiﬁed are detailed in table 2. Thirty-eight
per cent of MSH2 families, 12% of MSH6 families, 78% of MLH1
families and 25% of PMS2 families met the AMSI criteria.
Corresponding sensitivity for the AMSII criteria for identifying
mutations in the different genes were 62%, 48%, 87% and 38%.
Similarly, each of the clinical Bethesda criteria had low sensi-
tivity for identifying MSH6 and PMS2 mutations.
DISCUSSION
In this study in which all national activity was compiled, we
found that most families with MLH1 mutations were identiﬁed
by any of the clinical criteria used. The criteria that included
extracolonic cancers (AMSII) identiﬁed two out of three MSH2
mutations, whereas MSH6 mutations were not identiﬁed with
reasonable sensitivity by any of the single clinical criteria. As
these results were obtained after expanding all mutation-
Table 1 Continued
Type of
mutation/ gene Mutation
Effect of mutation
(veriﬁed or predicted) Family No
No of
mut+
IHC (missing
protein)
Inclusion criteria:
Amsterd.zz
Inclusion
criteria: BII xx Ref.
U90087 1 MSH2/MSH6 II 1, 2, 4 & 5
U1000173 2 MSH2/MSH6 II 1, 4 & 5
T382 3 MSH2/MSH6 0 1, 4 & 5
MSH2e12 c.1786_1788delAAT p.Asn596del D554 19 MSH2/MSH6 I & II 1, 2, 4 & 5 LOVD
D853 5 MSH2/MSH6 I & II 1, 2, 4 & 5
D3618 5 MSH2/MSH6 I & II 1, 2, 4 & 5
D3667 3 MSH2/MSH6 I & II 1, 2, 4 & 5
D3707 7 MSH2/MSH6 I & II 1, 2, 4 & 5
D4202 2 MSH2/MSH6 II 1, 2, 4 & 5
MSH6e4 c.2302_2304delCCT p.Pro768del H801 2 MSH2/MSH6 0 1, 2, 4 & 5 LOVD
4/14 H2160 5 ND 0 2, 4 & 5
S149 5 MSH2/MSH6 0 1 & 5
S647 3 MSH2/MSH6 II 2
Missense
MLH1e3 c.245C/T p.Thr82Ile S420yy 6 normal (MSI)** II 1, 4 & 5 LOVD
MLH1e16 c.1823C/A p.Ala608Asp S581yy 2 MLH1/PMS2 II 1, 2 & 4 LOVD
MSH6e4 c.2906A/G p.Tyr969Cys D2955yy 6 MSH6 I & II 1, 2, 4 & 5 LOVD
*Two pathogenic mutations in two branches in the same family.
yNo indications from IHC or microsatellite instability.
zReported to affect splicing and stability.
xLast nucleotide in exon; reported to cause skipping of exon.
{Shown in present study to give aberrant splicing.
**Normal protein expression, but microsatellite instability.
yyCosegregation with disease.
zzAmsterdam I and/or Amsterdam II.
xxBethesda II (revised), see text for details.
{{Not found to be reported in databases.
IHC, immunohistochemical analysis; LOVD, Leiden Open Variation Database (http://www.insight-group.org/mutations/); mut+, mutation carriers; ND, not done.
Table 2 Summary of deleterious variants according to gene, number of mutation carriers and which clinical criteria are fulﬁlled
Gene No of families No of mut+ Fraction of mutations (in %) No of mut+/family AMSI AMSII BII_1 BII_2 BII_4 BII_5
MSH2 65 248 50 3.82 25 (10.38) 40 (10.62) 61 (10.94) 46 (10.71) 58 (10.89) 57 (10.88)
MSH6 33 146 26 4.42 4 (10.12) 16 (10.48) 15 (10.45) 24 (10.72) 16 (10.48) 22 (10.67)
MLH1 23 98 18 4.26 18 (10.78) 20 (10.87) 23 (11.00) 20 (10.87) 23 (11.00) 23 (11.00)
PMS2 8 22 6 2.75 2 (10.25) 3 (10.38) 7 (10.88) 4 (10.50) 3 (10.38) 3 (10.38)
Total 129 514 100 3.98
AMSI/II, Amsterdam I/II criteria; BII, Bethesda II criteria; mut+, mutation carriers.
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Original articlecarrying kindreds, we consider them to be maximum estimates.
The sensitivities for detecting mutation-positive families upon
referral were lower.
The most sensitive single clinical criterion for identifying
MSH6 mutation carriers was the presence of two independent
primary cancers (BII_2) (table 2). This information is, however,
awaiting detailed validation of diagnoses in the families and may
not be easily obtainable when interviewing a family member.
We have recently reported that, when applied to a consecutive
series of unselected patients with CRC, the sensitivities of
AMSII and BII criteria were as low as 25% and 50%, respec-
tively.
12 Moreover, awareness of hereditary cancer among clini-
cians involved in diagnosis and treatment of CRC is low, and
families actually meeting the criteria may not be identiﬁed.
24
These points highlight the challenges associated with using
family history for detecting families with MMR mutations. Our
combined ﬁndings support the suggestion by the Mallorca group
to apply IHC and/or MSI analysis to all CRCs to identify MMR
mutation carriers.
25 As MSH6 mutation carriers are likely to
develop extracolonic cancers, it may be justiﬁed to suggest that
all cancer phenotypes associated with Lynch syndrome should
be subjected to IHC and/or MSI analysis and subsequent DNA
mutation analysis. Until such studies have been performed, we
remain cautious when discussing the prevalence of MSH6
mutations. Correspondingly, the current estimates of pene-
trance/expression of MSH6 mutations may be (partly) derived
from families fulﬁlling current clinical criteria.
26 27 These esti-
mates may be misleading, as they may reﬂect the criteria used to
select the families from which the estimates were derived.
MLH1 mutations were less common than assumed from
previous reports,
8 and MSH2 mutations accounted for almost
half of all kindreds with a mutation. Despite the fact that the
criteria used were insensitive for detecting MSH6 mutations, the
number of MSH6 mutation-carrying kindreds were higher than
MLH1 mutation-carrying kindreds.
None of the mutations were common enough to affect the
distribution signiﬁcantly, with respect to neither number of
mutation-carrying kindreds nor number of mutation-carrying
people. Despite the difference in prevalence of mutations in the
different genes, the mean number of mutation carriers per
family was similar for all the genes.
A Danish study reported a relatively high prevalence of MSH6
mutations.
20 If this were due to similarities between these
neighbouring populations, we would have expected to detect
founder mutation(s) in both populations, but this was not the
case. The reason for the similar results may be the study designs.
Both studies applied wide criteria for IHC and MSI analysis.
The number of carriers of PMS2 mutations was insufﬁcient
for sophisticated statistical analysis. Part of the explanation may
be that testing for PMS2 mutations has not been available for as
long as testing for mutations in the other genes. Also, most of
the few PMS2 mutation carriers were included in several
branches of one old family. Some of these branches were not
identiﬁed by IHC, but the tumours displayed MSI (MSI-high).
Thus, by performing only IHC and not MSI analysis to
prescreen for mutation testing, a few mutations may have been
missed. This indicates that MSI analysis is of importance if IHC
shows normal expression of all MMR genes. MMR mutations
cannot be excluded if neither analysis has been performed.
Technical problems involved in DNA PMS2 mutation analyses
are well known.
28e30 Current procedures (including both tech-
nical aspects and clinical criteria) may be insufﬁcient to detect
PMS2 mutations, and current estimates of prevalence of PMS2
mutations may be too low.
IHC was used as a selection criterion for mutation analysis
and could not be scored as a result. The result of all efforts to
examine selected families without abnormal IHC or MSI for
mutations was the identiﬁcation of a single mutation-carrying
family (family S254, MSH6 c.1405delT). The study was not
designed to assess sensitivity of IHC/MSI, and we will not
discuss this further. Our impression from other reports is,
however, that IHC and MSI analyses are more sensitive than
any clinical criteria for identifying kindreds carrying MSH2 or
MSH6 mutations, in particular,
11 12 and the present report is in
keeping with that notion.
In conclusion, we observed that 87% of families with an
MLH1 mutation, 62% with an MSH2 mutation, but less than
half of families with an MSH6 or PMS2 mutation were identi-
ﬁed by the AMSII criteria. Each of the clinical Bethesda criteria
when considered individually also showed low sensitivity. We
have, however, previously demonstrated that these criteria were
neither sensitive nor speciﬁc in an unselected series of CRC
cases. Our combined observations indicate that the prevalence of
MSH6 mutations may be higher than currently assumed, and
their penetrance and expression may differ from what is
currently assumed. These ﬁndings are in keeping with the
Mallorca guidelines, which recommend that MSI analysis and/or
IHC should be performed on all CRCs.
25 In addition, we suggest
that such testing should be applied to all incident cancers in the
Lynch syndrome tumour spectrum to increase the rate of
detection of MMR mutation carriers.
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